Molecular characterization of acute lymphoblastic leukemia (ALL) has greatly improved the ability to categorize and prognostify patients with this disease. In this study, we show that the proto-oncogene CDX2 is aberrantly expressed in the majority of cases with B-lineage ALL and T-ALL. High expression of CDX2 correlated significantly with the ALL subtype pro-B ALL, cALL, Ph þ ALL and early T-ALL. Furthermore, high expression of CDX2 was associated with inferior overall survival and showed up as a novel and strong risk factor for ALL in bivariate analysis. Functional analyses showed that overexpression of Cdx2 in murine bone marrow progenitors perturbed genes involved in lymphoid development and that depletion of CDX2 in the human ALL cell line Nalm6 inhibited colony formation. These data indicate that aberrant CDX2 expression occurs frequently and has prognostic impact in adult patients with ALL.
Introduction
With intensive risk adapted chemotherapy, stem cell transplantation and targeted therapies, the outcome of adult acute lymphoblastic leukemia (ALL) has improved in the past decades from o10 to 40-50%. 1, 2 In addition, great progress has been made in understanding the biology of ALL: recently, genome-wide analyses of ALL patients showed deletions and mutations of genes associated with lymphoid development, such as LEF1, TCF, PAX5, IKAROS and NOTCH1. [3] [4] [5] However, for the majority of ALL cases the molecular mechanisms driving the malignant transformation are unknown. Recently, data from experimental models and gene expression profiling in patients with acute myeloid leukemia (AML) have identified CDX2 as a powerful oncogene when aberrantly expressed in adult hematopoietic progenitor cells: [6] [7] [8] the 'caudal related homeobox gene' CDX2 belongs to the family of so-called 'ParaHox genes', which also includes CDX1, CDX4 and the GSH2 homeobox gene. 9 Normally expression of CDX2 is tightly regulated in the adult organism, with expression in the intestine but no expression in adult hematopoietic tissue. 10 It was shown that CDX2 is among the most frequent aberrantly expressed proto-oncogenes in AML, with up to 89% of AML cases with normal karyotype expressing CDX2. 8, 11 In AML patients, high expression levels of CDX2 were closely associated with HOX gene deregulation. 11 However, it was shown that besides Hox genes Cdx2 regulates other stem cell regulatory genes, such as Scl, Gata1 and Runx1. 12 Thus, aberrant expression of CDX2 might perturb the stem cell regulatory network at different levels.
We now report that CDX2 is aberrantly expressed in 81% of adult patients with ALL, and that high expression levels of this proto-oncogene predict poor treatment outcome in patients with this disease.
Materials and methods

Patient samples
Bone marrow or peripheral blood samples from 57 newly diagnosed adult patients with ALL were analyzed. Of these, 31 patients were enrolled between 2000 and 2004 in the protocols 06/99 and 07/03 of the German Multicenter Study Group for Adult ALL (GMALL). 13 Sixteen patients were enrolled in other multicenter protocols (GMALL Elderly 12/96, GMALL Elderly 01/03 and GMALL B-ALL/NHL 02). Ten patients were treated outside a study protocol. Patients gave written informed consent according to the Declaration of Helsinki. The studies were approved by the ethics board of the University Frankfurt am Main, Germany.
Quantitative PCR
Expression analyses were performed by TaqMan qRT-PCR using the Applied Biosystems 7900HT fast real-time PCR system with pre-designed gene expression assays purchased from Applied Biosystems (Assay IDs CDX2: Hs01078080_m1, HOXA7: Hs00600844_m1, HOXA9: Hs00365956_m1, HOXB6: Hs00980016_m1, TATA box binding protein (TBP): 4333769F; Applied Biosystems, Foster City, CA, USA). Reactions were run with 1 ml of cDNA containing the equivalent of 50 ng total RNA in a total volume of 20 ml. DC T values were obtained by normalization to the housekeeping gene TBP. For patients with undetectable DC T values (negative samples), the lowest possible DC T was calculated by subtracting the C T value of TBP from the maximum number of cycles (45 cycles). Note that DC T values are inversely correlated to gene expression levels. For the 'low density assay' (custom design LDA, array configuration 7), 92 different genes involved in self-renewal, proliferation and differentiation were selected. Each sample was run in duplicate and fold expression was calculated using the DDC T method after normalizing to b-actin.
Retroviral infection and in vitro assays
Primary mouse BM cells were transduced as described earlier. 7 For transduction of Cdx2, cells were co-cultured with irradiated (4000 cGy from a 137 Cs g-radiation) GP þ E86 Cdx2 producer cells. Clonogenicity of short hairpin RNA (shRNA) transduced Nalm6 cells was analyzed in the CFC assay as described earlier (Methocult H4434, Stemcell Technologies, Vancouver, British Colombia, Canada). 14 
Short hairpin RNA
Short hairpin RNA against CDX2 (NM_001265) were designed using the following website http://www.cshl.org/public/ SCIENCE/hannon.html. Four different shRNAs were obtained and cloned into the MSCV/LTRmiR30-PIG retroviral vector (kindly provided by Scott W Lowe, Howard Hughes Medical Institute, New York, USA). Short hairpin RNA sequences are available on request. Cell lines were retrovirally transduced as described earlier in Ahmed et al. 14 
Methylation analysis
Quantitative DNA methylation status of the CpG island surrounding the transcription start site of CDX2 (À181 to þ 163) 15 was assessed by pyrosequencing of bisulfite-treated genomic DNA. After bisulfite treatment of genomic DNA, the region of interest was amplified by the primer set CDX2_F (5 0 -TTGGT GTTTGTGTTATTATTAATAGAGTTTTGTAAATAT-3 0 ) and CDX2_R (5 0 -biotin-ATCCCAAAACAAACCTCACCATACTA-3 0 ). PCR product was immobilized to Streptavidin Sepharose HP beads (GE Healthcare, Waukesha, WI, USA) followed by annealing to the sequencing primer. For sequencing three different primers were used, which are available on request. CpG analysis was done with Pyro Q-CpG software (Biotage, Uppsala, Sweden).
Statistical analysis
Correlations of CDX2 expression level with other patient variables were analyzed using Fisher's exact test and the Mann-Whitney U-test. For this, patients were divided into groups with high and low/absent CDX2 expression using the median DC T value (7.14) as cut-off. Data from patients enrolled in the GMALL 06/99 and 07/03 studies were used for correlation of CDX2 expression level with different patient parameters as these patients underwent comparable risk stratification and received similar treatment regimens. Univariate survival analysis was performed with the log-rank test and Cox regression, CDX2 expression levels together with other potential risk factors for ALL were analyzed in a bivariate Cox proportional hazards model for overall survival. P-values o0.05 were considered statistically significant. Statistical analyses were performed using SPSS (SPSS Inc, Chicago, IL, USA).
Results
CDX2 is aberrantly expressed in the majority of patients with acute lymphoblastic leukemia
Fifty-seven samples from adult patients with newly diagnosed ALL (Table 1) were analyzed for CDX2 expression levels by qRT-PCR. In contrast to human normal hematopoietic bone marrow, CD34 þ 7,8 or peripheral blood mononuclear cells (PBMCs), 46 of 57 ALL patients (81%) were positive for CDX2 expression. Among the CDX2-positive cases, expression levels varied substantially between different ALL subgroups: the median expression level was 16-fold higher in pro-B ALL compared with mature B-ALL and 29-fold higher in early T-ALL compared with thymic T-ALL ( Figure 1a , Table 1 ). When high and low CDX2 expression levels were defined as below or above the median DC T value, none of the patients with mature B-ALL or thymic T-ALL had high CDX2 expression, whereas all the patients with pro-B ALL, 8 of 10 patients with cALL and 8 of 11 patients with Ph þ ALL (10 pre-B/c-ALL and 1 pro-B ALL) showed high CDX2 expression (Po0.001) (Figure 1b) . Of note, ALL subtypes such as pro-B ALL expressed CDX2 more than four-fold higher than AML cases with normal karyotype, described as the AML subgroup with highest CDX2 expression levels 11 (Figure 1a Figure 3 High expression of CDX2 is associated with poor treatment outcome in acute lymphoblastic leukemia (ALL). Kaplan-Meier plot for overall survival of patients with high versus low/absent CDX2 expression levels. of CDX2 and expression of the leukemogenic HOXA7 or HOXA9 genes. There was a correlation between CDX2 and HOXB6 expression, but of borderline significance (P ¼ 0.048, Mann-Whitney U-test) (Figure 1c) . We tested promoter hypomethylation as a potential cause for aberrant CDX2 expression, but did not detect any difference in methylation of a region surrounding the transcriptional start site of CDX2 8, 15 between CDX2-positive and CDX2-negative ALL cases (Table 2) . We next analyzed whether shRNA-mediated CDX2 depletion would affect the CDX2-positive human pre-B ALL cell line Nalm6. In the CFC assay, Nalm6 cells transduced with HU_672_CDX2 (inducing a 49% reduction of CDX2 expression at the mRNA level by qRT-PCR) generated 33% fewer colonies compared with empty vector control and the non-active shRNA HU_673_CDX2 (data not shown), indicating an important role of CDX2 for the growth of this cell line.
Overall survival
CDX2 in
Besides Hox genes, 11 enforced expression of Cdx2 in normal murine progenitors significantly upregulated genes involved in lymphopoiesis, such as Lef1 (3.9-fold), Tcf3 (13.3-fold), Flt3 (4.2-fold) and Id3 (10.2-fold) (Figure 2 ).
High CDX2 expression levels are associated with poor treatment outcome in ALL When we analyzed the expression of CDX2 in different risk groups of ALL patients (according to Raff et al. 13 ), most very high risk (VHR) and high risk (HR) patients showed high CDX2 expression, in contrast to the standard risk (SR) group (P ¼ 0.007 according to Fisher's exact test) ( Table 3) .
In a univariate analysis, high CDX2 expression levels were significantly associated with inferior OS (hazard ratio (HR) 4.2, 95% CI: 1.1-15.7) (Figure 3 ): survival rate two years after diagnosis was 86% of patients with low/absent and 52% of patients with high CDX2 expression levels (P ¼ 0.019, log rank test). In bivariate Cox regression, the CDX2 expression level remained a significant risk factor even after adjusting for the risk factors age and presence of molecular markers. The hazard ratio for CDX2 did not change substantially after adjusting for age (HR for CDX2 3.3, 95% CI: 0.86-12.85), presence of molecular aberrations (HR for CDX2 4.0, 95% CI: 1.07-15.13), ALL subtype (HR for CDX2 1.8, 95% CI: 0.36-8.96), ALL risk category (HR for CDX2 2.9, 95% CI: 0.69- Abbreviations: ALL, acute lymphoblastic leukemia; Ph + , philadelphia chromosome t(9;22)(q34;q11) positive. Quantitative analysis of methylation status of CpG islands surrounding the transcription start site of CDX2 from the position À181 to +163 (15) in six ALL patients positive for CDX2 (2x c-ALL, 2x pro-B-ALL, 2x early T-ALL) and three patients negative for CDX2 (1x B-ALL, 1x early T-ALL, 1x thymic T-ALL). The table indicates the methylation per site and the average methylation level of all 24 CpG sites located within the analyzed region. 
Discussion
This report describes for the first time that the proto-oncogene CDX2 is aberrantly expressed in the majority of patients with Blineage or T-lineage ALL. Thus, it extends our knowledge about the deregulation of this transcription factor that was reported earlier to be one of the most frequent ectopically expressed proto-oncogenes in AML, 8, 11 and underlines that aberrant expression of this homeobox gene is not restricted to myeloid malignancies. This aberrant expression of CDX2 in human leukemias stands in clear contrast to highly related genes such as CDX4 or CDX1, which were not expressed in our series of AML patients or were detected only in a minor fraction of patients with AML. 11, 16 Furthermore, analyses of CDX4 expression in our series of ALL samples did not show expression of this ParaHox gene (data not shown). The reason for this is unknown. But data from experimental murine models indicate that acquiring aberrant CDX2 expression might provide a greater growth advantage for the cell than acquiring aberrant CDX4 expression as constitutive expression of Cdx2 seems to be much more leukemogenic than Cdx4 in a murine BM transplantation model. 16 So far the leukemogenic potential of Cdx2 has been linked to its ability to deregulate HOX gene expression: it has been shown that Cdx2 is able to upregulate expression of 5 0 located Hox genes known to be leukemogenic and that this ability depends on its N-terminal transactivation domain. 11 However, it is unclear whether CDX2 can also exert its oncogenic effect by other pathways. This might be particularly true in adult patients with ALL, in which HOX gene deregulation is comparably rare compared with AML. 5 This could indicate that in ALL the leukemogenic effect of CDX2 does not depend on HOX gene perturbation to the same extent as in AML, and that CDX2 mediates its oncogenic potential through different gene networks in ALL. When we analyzed gene transcription after retroviral induction of aberrant Cdx2 expression in murine BM progenitor cells, we observed that besides Hox genes also factors involved in lymphoid development such as Lef1 were upregulated. Recently, we showed that aberrant expression of this factor caused AML and also B-lineage ALL in transplanted mice. 17 Therefore, the aberrant CDX2 expression might initiate or support myeloid as well as lymphoid leukemogenesis, Table 3 Correlation of CDX2 expression levels with clinical patient characteristics Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; HR, high risk; PB, peripheral blood; Ph + , Philadelphia chromosome t(9;22)(q34;q11) positive; SR, standard risk; VHR, very high risk; WBC, white blood count. The correlation between different patient characteristics and high CDX2 expression levels is shown.
CDX2 in acute lymphoblastic leukemia S Thoene et al probably depending on the differentiation stage of the cell initially affected by CDX2 overexpression. The underlying mechanism for aberrant CDX2 expression in human leukemias is unknown: we did not detect any difference in promoter methylation of the CDX2 gene between CDX2-positive and CDX2-negative ALL cases. The same was reported for patients with AML, where also no mutation in the coding region or gene amplification was detected. 8, 15 That aberrant CDX2 expression has functional relevance in ALL was supported by the observation that shRNA-mediated CDX2 depletion compromised the clonogenic growth potential of the CDX2-positive human pre-B ALL cell line Nalm6. Furthermore, high expression of CDX2 was mostly found in ALL patients with a high-risk profile. In line with this, high expression of CDX2 was associated with a significantly inferior OS. Remarkably and despite the limited patient number available for this analysis, CDX2 expression level remained a significant and strong risk factor even after adjusting for the risk factors age and presence of molecular markers in bivariate analyses.
Altogether, these results show that aberrant expression of CDX2 is a frequent event in adult patients with ALL. Delineating the underlying molecular mechanisms of aberrant CDX2 expression and characterizing factors mediating CDX2-induced leukemogenesis will help to understand important steps in leukemogenesis, which are common in both lymphoid and myeloid leukemias.
